drugset / Trial / NCT04566978
89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)
RandomizedSequentialOpen-labelDiagnostic
Summary
The main purposes of this study include: Looking at the way the body absorbs, distributes, and gets rid of 89Zr-DFO-REGN3767 Finding the best dose amount of 89Zr-DFO-REGN3767 Finding the best time for PET scanning after injection of 89Zr-DFO-REGN3767
Timeline
- Start
- 2020-09-11
- Primary completion
- 2025-03-21
- Completion
- 2025-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FIANLIMAB DFO ZR-89 | Monoclonal antibody | 2 mg | — |
| Subject | FIANLIMAB DFO ZR-89 | Monoclonal antibody | 5 mg | — |
| Subject | FIANLIMAB DFO ZR-89 | Monoclonal antibody | 10 mg | — |
| Subject | FIANLIMAB DFO ZR-89 | Monoclonal antibody | 20 mg | — |